A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne

Conclusions: All clascoterone cream concentrations were well tolerated with no clinically relevant safety issues noted. Clascoterone 1% BID treatment had the most favorable results and was selected as the best candidate for further clinical study and development. Two Phase 3 investigations of clascoterone topical cream, 1% for the treatment of moderate-to-severe acne vulgaris in individuals ≥9 years recently concluded. J Drugs Dermatol. 2019;18(6):570-575. PMID: 31251550 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31251550?dopt=Abstract

Source: Journal of Drugs in Dermatology - June 30, 2019 Category: Dermatology Tags: J Drugs Dermatol Source Type: research